Cantabria Labs Launches QuaPharma Contract Manufacturing Facility in Guarnizo
Cantabria Labs has launched QuaPharma, a new contract development and manufacturing organization (CDMO) operating out of Guarnizo, Spain, with an initial workforce of 70 industry professionals, according to regional reporting by ifomo.es. The specialized subsidiary arrives to provide pharmaceutical outsourcing services across Europe without retaining any proprietary brand names.
Industrial Capacity and Production Lines at Guarnizo
The new manufacturing operation is housed in the Guarnizo Industrial Estate, utilizing eight dedicated production lines designed for multiple drug formats. The facility’s output is projected to reach up to 30 million production units annually.
QuaPharma Protects Intellectual Property as Contract Manufacturer
QuaPharma operates exclusively as a contract manufacturer without developing or marketing its own pharmaceutical brands. This operational structure aims to guarantee competitive neutrality for external laboratories and secure the intellectual property rights of client companies. Enrique Quintana leads the new enterprise as Chief Executive Officer, bringing a 30-year career within the pharmaceutical sector to the project.
Integrated Drug Lifecycle Services
The organization provides an end-to-end service model covering the entire lifecycle of pharmaceutical products under a single provider. Client laboratories can outsource all development phases through QuaPharma, spanning galenic formulation, pilot batch creation, stability testing, regulatory registration, and full-scale commercial manufacturing. This consolidated approach allows the company to accelerate time-to-market schedules while meeting complex regulatory requirements across international jurisdictions.
What the Guarnizo Facility Manufactures and Produces
What products does the Guarnizo facility manufacture?
The facility features eight manufacturing lines dedicated to liquids, semisolids such as creams and gels, syrups, solutions, and solid forms including tablets and capsules.
Who leads the new pharmaceutical company?
Enrique Quintana serves as Chief Executive Officer of QuaPharma, drawing on three decades of prior experience in the pharmaceutical industry.
What is the projected annual production capacity?
The manufacturing plant is equipped to produce up to 30 million units per year.